<DOC>
	<DOCNO>NCT01229397</DOCNO>
	<brief_summary>The study aim evaluate immunogenicity single full ( 0.5 mL ) dose 0.25 mL 2-dose regime Inflexal V unprimed child age 6 - &lt; 36 month , use EMA guideline re-registration seasonal influenza vaccine adult ( age ≥18 ≤60 year ) reference .</brief_summary>
	<brief_title>Immunogenicity Safety Single 0.5 mL Dose Inflexal V With 0.25 mL 2-dose Regimen Inflexal V</brief_title>
	<detailed_description />
	<criteria>Healthy male female child Aged ≥6 &lt; 36 month Day 1 Born gestational age ≥37 week Written inform consent No previous influenza vaccination Acute respiratory infection acute disease Acute febrile illness ( ≥38.0 °C ) Past vaccination influenza vaccine , include vaccination influenza strain A/California/7/2009 ( H1N1 ) like virus Laboratoryconfirmed infection influenza strain , include pandemic influenza strain H1N1 ( A/California/7/2009 ( H1N1 ) like virus ) Known hypersensitivity vaccine component Known history egg protein allergy severe atopy Known blood coagulation disorder Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose study vaccine , incl . oral corticosteroid dosage ≥0.5 mg/kg/d prednisolone equivalent ≥14 day ( inhaled topical steroid allow ) Known immunodeficiency ( include leukemia , cancer , HIV seropositivity ) Investigational medicinal product receive past 3 month ( 90 day ) Treatment immunoglobulin blood transfusion ( ) receive past 3 month ( 90 day ) Vaccination MMR vaccine past 4 week , plan within study period Participation another clinical trial Child legal charge investigator employee study site , live household investigator/employee and/or dependent investigator/employee Suspected noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunisation</keyword>
</DOC>